Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafenoquine and Primaquine PK in Lactating Women
NCT04984759Phase 4Withdrawn
- Sponsor
- University of Oxford
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tafenoquine and primaquine in Plasmodium vivax malaria (3 arms), sponsored by University of Oxford. Primary endpoint: Excretion of tafenoquine and primaquine in colostrum, transitional milk and mature milk. Planned start Jul 2023; status: withdrawn.
02
Drugs
tafenoquineprimaquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT04984759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984759.